Digipath
Announces
Plans to Expand Cannabis Testing Internationally
Starting In
Colombia, Nevada Cannabis Market Leader Ready to Pursue
International Markets
LAS
VEGAS, NV -- January 02, 2019 --
InvestorsHub NewsWire -- Digipath,
Inc. (OTCQB:
DIGP), a
service
oriented independent testing
laboratory,
data
acquisition and media firm focused on
the developing
cannabis
and
hemp markets,
is pleased to announce its plans
to
expand internationally.
Colombia is the first foreign market in which Digipath plans to
provide cannabis
testing
for
both
local consumers and cannabis
exporters.
Colombia
is projected to be a significant cannabis exporter due to its
climate and low cost of production and
all
cannabis products
will
need to be
tested for
potency and safety prior
to export to any other
country.
Colombia
formally legalized
medical marijuana
in 2015. The
country has realigned its interests to the export market in its
current policy operations and is preparing to produce 40.5 tons of
cannabis per year, starting in 2019.
Digipath
has retained legal representation in Colombia, hired a local
operations manager and is evaluating potential
locations.
"Clearly,
international expansion presents
a tremendous opportunity for Digipath and its shareholders," stated
Todd Denkin, CEO, Digipath, Inc. "A fully-realized presence
in South
America could
significantly
increase
our customer
base. We
expect Colombia
to be
one
of the
market leaders
in
cannabis,
hemp and CBD production and
are excited about the possibilities."
Through
Digipath's Chief Science Officer Dr. Cindy Orser's work in
Nevada,
Digipath Labs
helped pioneer
cannabis lab testing protocols and
implement
one
of the
nation's most stringent cannabis safety regulations.
This commitment to excellence has
now positioned Digipath Labs
as a
market leader in the
cannabis
lab testing industry.
The Company intends to carry
the
testing standards it has developed
and proven in Nevada into these
new international markets.
About Digipath, Inc. & Digipath Labs, Inc.
Digipath, Inc. supports
the cannabis industry's best practices for reliable testing, data
acquisition, cannabis education and training, and brings unbiased
cannabis news coverage to the cannabis industry. Digipath
Labs provides
pharmaceutical-grade analysis and testing to the cannabis industry
to ensure producers, consumers, and patients know exactly what is
in the cannabis they ingest and to help maximize the quality of its
client's products through analysis, research, development, and
standardization.
Digipath Investor Relations & Financial Media
info@integrityir.com
Toll
Free: (888) 216-3595
www.IntegrityIR.com
Information
about Forward-Looking Statements
This
press release contains "forward-looking statements" that include
information relating to future events. Forward-looking statements
should not be read as a guarantee of future performance or results
and will not necessarily be accurate indications of the times at,
or by, which that performance or those results will be achieved.
Forward-looking statements are based on information available at
the time they are made and/or management's good faith belief as of
that time with respect to future events and are subject to risks
and uncertainties that could cause actual performance or results to
differ materially from those expressed in, or suggested by, the
forward-looking statements. Important factors that could cause
these differences include, but are not limited to: the Company's
need for additional funding, the demand for the Company's products,
governmental regulation of the cannabis industry, the Company's
ability to maintain customer and strategic business relationships,
the impact of competitive products and pricing, growth in targeted
markets, the adequacy of the Company's liquidity and financial
strength to support its growth, and other risks that may be
detailed from time-to-time in the Company's filings with the United
States Securities and Exchange Commission. For a more detailed
description of the risk factors and uncertainties affecting
Digipath, please refer to the Company's recent Securities and
Exchange Commission filings, which are available at
www.sec.gov. The Company
undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise.